Fagron announces 90 day beyond-use-dating study results for their industry leading LETS GEL KIT.
NEW STUDY SUPPORTS EXTENDED BEYOND USE DATING IN FAGRON UNIT DOSE SRYINGE |
| [28-November-2017] |
| ST. PAUL, Minn., Nov. 28, 2017 /PRNewswire/ -- Fagron announces 90 day beyond-use-dating (BUD) study results for their industry leading LETS GEL KIT™, a rapid topical anesthesia convenience pack, when stored in Fagron 3 mL unit dose syringes. New LETS GEL KIT™, launched summer 2017, features SuturaGel™, a specially formulated gel to minimize medication run-off. Included in this easy-to-use convenience pack are pre-weighed active ingredients--Lidocaine Hydrochloride, Epinephrine Bitartrate, Tetracaine Hydrochloride, Sodium Metabisulfite, topical syringes, and SuturaGel™. “We are delighted with our BUD study results that were performed at an independent laboratory,” stated Ronaldo Steentjes, General Manager of Fagron, Inc. “Our investment in research and development further represents Fagron’s commitment to provide quality, proven products to the US market and abroad. Fagron, Inc. routinely introduces innovative products to the market based on research completed in their own R&D center. To find out more, visit fagron.us. About Fagron, Inc. Fagron, Inc., is headquartered in St. Paul, Minnesota. Since 1980, Fagron, Inc. has been an FDA-registered pharmaceutical supplier, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk pharmaceutical ingredients are purchased from reputable, registered, and validated manufacturers. As a R&D scientific pharmaceutical compounding supplier, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist and improves patients’ quality of life. Contact Fagron, Inc. today at us.fagron.com/en-us/contact. About Fagron North America Fagron North America is a group of innovative, scientific pharmaceutical companies that focus on optimizing and innovating personalized pharmaceutical care. As part of the world’s leading pharmaceutical compounding company, operating in 34 countries, we act locally and think globally. Fagron North America is fully integrated with facilities that specialize in 503A Compounding, 503B Human Drug Outsourcing, and providing pharmacists with high quality APIs, supplies, education and technical support. For more information, visit fagron.us/more.
View original content with multimedia:http://www.prnewswire.com/news-releases/fagron-inc-announces-stability-data-on-lets-gel-kit-for-rapid-topical-anesthesia-300562790.html SOURCE Fagron, Inc. |
